EGFR and neoplasm: However, in contrast to lung cancer, activating mutations in exons 19 and 21 of EGFR were not detected in 16 kidney tumours (Lynch et al, 2004) and, clinically, tumour regressions following EGFR inhibition have been minimal (Amato, 2005).